SCHEMBL26506563

SCHEMBL26506563

COC(=O)c1ccccc1Oc1nc(Nc2ccc(N3CCCC3)cc2)ncc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 2/20 0.53
▸ PRKAA2 P54646 1/20 0.53
▸ PRKAA1 Q13131 1/20 0.53
▸ ULK2 Q8IYT8 1/20 0.53
▸ CDK4 P11802 3/20 0.51
▸ CCND1 P24385 3/20 0.51
▸ CDK1 P06493 1/20 0.51
▸ CDK2 P24941 1/20 0.51
▸ MAP3K7 O43318 5/20 0.49
▸ MAP2K1 Q02750 5/20 0.49
▸ MAPK1 P28482 4/20 0.49
▸ FLT3 P36888 1/20 0.47
▸ PKMYT1 Q99640 1/20 0.47
▸ STAT6 P42226 2/20 0.47
▸ LCK P06239 3/20 0.46
▸ JAK3 P52333 1/20 0.46
▸ BTK Q06187 1/20 0.46
▸ TNK2 Q07912 1/20 0.46
▸ IGF1R P08069 1/20 0.46
▸ NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26506540 0.93 IGF1R (0.56) ULK1PRKAA2PRKAA1ULK2MAP3K7
SCHEMBL26506537 0.93 CDK4 (0.60) ULK1PRKAA2PRKAA1ULK2CDK4
SCHEMBL26506594 0.92 LCK (0.56) ULK1PRKAA2PRKAA1ULK2CDK4
SCHEMBL26506589 0.85 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2
SCHEMBL26506579 0.85 ULK1 (0.59) ULK1PRKAA2PRKAA1ULK2CDK1
SCHEMBL26506551 0.84 ULK1 (0.61) ULK1PRKAA2PRKAA1ULK2MAPT
SCHEMBL26506580 0.84 ULK1 (0.58) ULK1PRKAA2PRKAA1ULK2CDK4
SCHEMBL26506558 0.82 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2CDK4
SCHEMBL26506586 0.82 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2CDK2
SCHEMBL26506572 0.82 ULK1 (0.56) ULK1PRKAA2PRKAA1ULK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME ULK2, ULK1, ULK3 ULK1 2/4885PRKAA2 130/4885PRKAA1 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback